Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
565-02-005 ISMRM Abstract

7T SWI Intratumoral Susceptibility Signals Predict Ki-67 Proliferation and TERT Promoter Mutation in Glioma

Primary: Neuro - Head & Neck/ENT
Secondary: Physics & Engineering - High-Field MRI
565-02-005 · Neuro-Oncology and Ear, Nose, and Throat Cancer · Wednesday, 13 May, 9:15 AM–10:10 AM · Digital Posters Row F
Keywords: Diagnosis/Prediction Glioma Susceptibility-weighted Imaging Molecular Markers
Accepted
Fengwei Yu 1, Ke Li1, zilong Li1, Suyi Zhou1, Yi-Cheng Hsu2, Jiafei Chen1, Zhiming Zhen1, Wei Chen1
1Department of Radiology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China
2MR Research Collaboration, Siemens Healthineers Ltd., Shanghai, China
Presenting Author: Fengwei Yu

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J]. Neuro Oncol, 2021, 23(8): 1231-51. DOI:10.1093/neuonc/noab106. [doi]
2. LI F, WANG D, WANG N, et al. A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma [J]. Sci Rep, 2024, 14(1): 20334. DOI:10.1038/s41598-024-71275-9. [doi]
3. MURUGAN A K, KANNAN S, ALZAHRANI A S. TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance [J]. Biochim Biophys Acta Rev Cancer, 2025, 1880(1): 189243. DOI:10.1016/j.bbcan.2024.189243. [doi]
4. LIANG X, TAN S, CHEN Y, et al. Bioinformatics exploration of SPHKAP's role in IDH-mutant glioma involving energy metabolism, prognosis, and immune modulation [J]. J Neuroimmunol, 2025, 402: 578570. DOI:10.1016/j.jneuroim.2025.578570. [doi]
5. ZHU Z, LAN Y, WANG L, et al. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients [J]. BMC Cancer, 2020, 20(1): 1072. DOI:10.1186/s12885-020-07552-3. [doi]
6. MARTíN-NOGUEROL T, SANTOS-ARMENTIA E, RAMOS A, LUNA A. An update on susceptibility-weighted imaging in brain gliomas [J]. Eur Radiol, 2024, 34(10): 6763-75. DOI:10.1007/s00330-024-10703-w. [doi]
7. HORBINSKI C, NABORS L B, PORTNOW J, et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022 [J]. J Natl Compr Canc Netw, 2023, 21(1): 12-20. DOI:10.6004/jnccn.2023.0002. [doi]
8. LOUIS D N, WESSELING P, ALDAPE K, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading [J]. Brain Pathol, 2020, 30(4): 844-56. DOI:10.1111/bpa.12832. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/565-02-005